Literature DB >> 27469298

A review of the predictive role of functional imaging in patients with mucosal primary head and neck cancer treated with radiation therapy.

Myo Min1,2,3, Peter Lin2,4,5, Gary Liney1,2,3,6, Mark Lee1,2, Dion Forstner1,2,3, Allan Fowler1, Lois Holloway1,2,3,6,7.   

Abstract

Advanced radiotherapy techniques, such as intensity-modulated radiotherapy, have been reported to reduce toxicities by improving the dose conformity in mucosal primary head and neck cancer (MPHNC). However, to further optimize the therapeutic ratio, details on individual patient and disease characteristics may be necessary to tailor treatments. This is likely to include identifying poor responders for treatment intensification and good responders for de-escalation strategies. Non-invasive, repeatable imaging biomarkers are attractive modalities in both pre-treatment and intra-treatment response prediction with a view to individualized treatment options. This review has assessed the current literature on the prognostic/predictive role of widely available functional imaging (FI) studies such as fMRI(functional magnetic resonance imaging), functional computed tomography (fCT) and positron-emission-tomography(PET). A literature search was carried out using Medline, Embase and PubMed. Studies were included if imaging was undertaken pre and/or during radiotherapy (with or without the addition of chemotherapy and/or surgery). A total of 99 relevant studies were identified: 14 fMRI, 10 fCT, 59 FDG-PET and 16 non-FDG-PET studies. These articles were reviewed to identify imaging parameters demonstrating a correlation with patient outcome or a factor considered to impact on patient outcome and thus likely to be of potential predictive value in MPHNC and associated future radiotherapy treatment directions. Several studies have demonstrated that both pre-treatment and mid-treatment FDG-PET is predictive of outcomes. However, further studies are required to confirm the role of other imaging studies including fMRI and PET using other tracers. There is large heterogeneity within and between published studies, including tumour sites, treatment options, outcome endpoints and parameters assessed. We propose a minimum set of factors that should be reported and make recommendations for studies evaluating the predictive utility in MPHNC.
© 2016 The Royal Australian and New Zealand College of Radiologists.

Entities:  

Keywords:  functional imaging; head and neck cancer; magnetic resonance imaging; positron emission tomography; predictive role

Mesh:

Year:  2016        PMID: 27469298     DOI: 10.1111/1754-9485.12496

Source DB:  PubMed          Journal:  J Med Imaging Radiat Oncol        ISSN: 1754-9477            Impact factor:   1.735


  5 in total

1.  PET-based prognostic survival model after radiotherapy for head and neck cancer.

Authors:  Joël Castelli; A Depeursinge; A Devillers; B Campillo-Gimenez; Y Dicente; J O Prior; E Chajon; F Jegoux; C Sire; O Acosta; E Gherga; X Sun; B De Bari; J Bourhis; R de Crevoisier
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-08-21       Impact factor: 9.236

2.  Nodal parameters of FDG PET/CT performed during radiotherapy for locally advanced mucosal primary head and neck squamous cell carcinoma can predict treatment outcomes: SUVmean and response rate are useful imaging biomarkers.

Authors:  Peter Lin; Myo Min; Mark Lee; Lois Holloway; Dion Forstner; Victoria Bray; Allan Fowler
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-12-21       Impact factor: 9.236

3.  Automated model-based quantitative analysis of phantoms with spherical inserts in FDG PET scans.

Authors:  Ethan J Ulrich; John J Sunderland; Brian J Smith; Imran Mohiuddin; Jessica Parkhurst; Kristin A Plichta; John M Buatti; Reinhard R Beichel
Journal:  Med Phys       Date:  2017-11-23       Impact factor: 4.071

4.  A feasibility study on adaptive 18F-FDG-PET-guided radiotherapy for recurrent and second primary head and neck cancer in the previously irradiated territory.

Authors:  Julie Schatteman; Dirk Van Gestel; Dieter Berwouts; Werner De Gersem; Geert De Kerf; Wilfried De Neve; Bie De Ost; Ana Maria Luiza Olteanu; Sylvie Rottey; Tom Vercauteren; Ingeborg Goethals; Fréderic Duprez
Journal:  Strahlenther Onkol       Date:  2018-03-19       Impact factor: 3.621

Review 5.  The Promise of Novel Biomarkers for Head and Neck Cancer from an Imaging Perspective.

Authors:  Loredana G Marcu; Paul Reid; Eva Bezak
Journal:  Int J Mol Sci       Date:  2018-08-24       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.